Ipsen to acquire ImCheck Therapeutics from EQT Life Sciences for €1bn.

Ipsen, a biotechnology company, agreed to acquire ImCheck Therapeutics, a private French biotech company, from EQT Life Sciences, a private equity firm, for €1bn. "This transaction is an extraordinary milestone for ImCheck and puts the spotlight on groundbreaking science originating from French academia. EQT Life Sciences' support has extended far beyond financing – their strategic guidance and confidence in my leadership has been instrumental in our success. Together, we have advanced pioneering science from concept to late-stage clinical development, demonstrating what visionary investors and dedicated teams can accomplish together," Pierre d'Epenoux, ImCheck Therapeutics CEO.